From each FDA label

Do GLP-1s cause bloating?

Bloating is in the main trial table of 4 labels. The highest rate printed is 8% on Foundayo 17.2 mg (3% on placebo) and the lowest 4% on Zepbound 15 mg (2% on placebo). Separate trials, so not a ranking. Byetta lists it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 27, 2026.

Rate against placebo

How often bloating happened in each medicine's trials

At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.

MedicineDoseOn itOn placeboDifferenceLabel
Foundayo17.2 mg8%3%+5 pointsDailyMed
Wegovy2.4 mg7%5%+2 pointsDailyMed
Saxenda3 mg4.5%3%+1.5 pointsDailyMed
Zepbound15 mg4%2%+2 pointsDailyMed
Word for word

What each label says about bloating

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%), and diarrhea (30% vs. 16%). Other reactions that occurred at a higher incidence among Wegovy injection-treated adult patients included dyspepsia, abdominal pain, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, gastritis, hemorrhoids, and hiccups.

Label revised Jun 18, 2026. DailyMed

Rybelsus and Ozempic tablets

  • In addition to the reactions in Table 2, the following gastrointestinal adverse reactions with a frequency of <5% occurred in semaglutide tablets -treated patients (frequencies listed, respectively, as 14 mg once daily, 7 mg once daily and placebo): abdominal distension (3%, 2% and 1%), dyspepsia (0.6%, 3%, 0.6%), eructation (2%, 0.6%, 0%,), flatulence (1%, 2%, 0%), gastroesophageal reflux disease (2%, 2%, 0.3%) and gastritis (2%, 2%, 0.8%).

Label revised Jan 30, 2026. DailyMed

Mounjaro

  • The following gastrointestinal adverse reactions were reported more frequently in Mounjaro-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).

Label revised Aug 27, 2026. DailyMed

Trulicity

  • The following GI adverse reactions were reported more frequently in Trulicity-treated patients than placebo -treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).

Label revised Jun 16, 2026. DailyMed

Saxenda

  • The percentage of patients reporting nausea declined as treatment continued. Other common adverse reactions that occurred at a higher incidence among Saxenda-treated patients included diarrhea, constipation, vomiting, dyspepsia, abdominal pain, dry mouth, gastritis, gastroesophageal reflux disease, flatulence, eructation and abdominal distension.

Label revised Feb 25, 2026. DailyMed

Byetta: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine. Ozempic, Zepbound, Foundayo, Victoza: no finding on this in the sections read here.

Not from trials

Reports to FDA about bloating

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
OzempicAbdominal distension: 1,65470,863
ByettaAbdominal distension: 1,30552,087
TrulicityAbdominal distension: 1,16687,279
MounjaroAbdominal distension: 1,04997,440
ZepboundAbdominal distension: 89380,835
VictozaAbdominal distension: 61841,462
WegovyAbdominal distension: 37025,993
Rybelsus and Ozempic tabletsAbdominal distension: 1287,758
SaxendaAbdominal distension: 1127,270
FoundayoAbdominal distension: 993,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Bloating on a GLP-1: common questions

Which GLP-1 causes the most bloating?

No trial here ranks them. By the rates each label prints, Foundayo 17.2 mg is highest at 8% (placebo 3%) and Zepbound 15 mg lowest at 4% (placebo 2%). These come from separate trials with different people and doses, so compare each to its own placebo group.

Does Foundayo cause bloating?

In its FDA label, 8% of people taking Foundayo 17.2 mg reported bloating, against 3% on placebo.

Does Wegovy cause bloating?

In its FDA label, 7% of people taking Wegovy 2.4 mg reported bloating, against 5% on placebo.

Does Saxenda cause bloating?

In its FDA label, 4.5% of people taking Saxenda 3 mg reported bloating, against 3% on placebo.

Does Zepbound cause bloating?

In its FDA label, 4% of people taking Zepbound 15 mg reported bloating, against 2% on placebo.

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.